Sweden Says Yes To Vazkepa Reimbursement But England Says No For Now

 
• By Neena Brizmohun

Amarin’s treatment is to be made available in Sweden for cardiovascular risk reduction at a price of SEK1,640 per month. But England’s health technology assessment body has concerns over the drug’s cost effectiveness.

Balance scales with capsules pills and money coins. 3d render.
Sweden and England have been assessing the cost-effectiveness of Vazkepa • Source: Alamy

More from Europe

More from Geography